100XBIO, founded in Woburn, Massachusetts, is dedicated to advancing T cell therapy by simplifying tools for testing T cell response. The company's core mission is to deliver significantly more data on antigen specificity of T cells from limited sample volumes and accurately match antigen specificity with TCR sequences. Their main product is a technology that enables multiplex antigen-specific T cell activation detection, offering up to 100 cycles of antigen-specific stimulation and live T cell imaging.
Notable affiliated individuals and investors have not been publicly detailed. Key achievements include the development of their proprietary technology that provides 100 times more data from small samples, which has the potential to revolutionize T cell therapy research and applications. The overall impact of 100XBIO lies in its ability to enhance the precision and efficiency of T cell response testing, thereby contributing significantly to advancements in immunotherapy and personalized medicine.
